How does Duocarmycin induce cytotoxicity in targeted cells?

Once internalized, Duocarmycin, the cytotoxic component of the ADC, binds to DNA within the cancer cells. It causes alkylation and minor groove binding, which leads to DNA damage, disrupting the DNA replication process and ultimately causing cell death.

What are the advantages of using this ADC for pre-screening monoclonal antibodies?

The Protein G-Duocarmycin ADC offers a cost-effective and efficient method for pre-screening monoclonal antibodies as potential ADC candidates. It allows researchers to assess the therapeutic potential of antibodies by observing the cytotoxic effect of Duocarmycin on cells targeted by the antibodies under investigation.

Are there specific cancer types that are more responsive to treatment with Protein G-Duocarmycin ADC?

The efficacy of the Protein G-Duocarmycin ADC is particularly notable in cancers that express Fc receptors, which are targeted by the Protein G component of the ADC. Such cancers include certain leukemias, lymphomas, and some solid tumors.

What experimental conditions are recommended for using the Protein G-Duocarmycin ADC in laboratory research?

Optimal experimental conditions include using the ADC at concentrations determined through preliminary dose-response experiments. The cell culture should express Fc receptors to ensure ADC binding and internalization. Conditions such as incubation time and temperature should be optimized based on specific cell line characteristics.

How does the linker in the Protein G-Duocarmycin ADC enhance its stability and efficacy?

The linker used in this ADC is designed to be stable in the bloodstream, which prevents premature release of Duocarmycin. This stability ensures that the cytotoxic payload is only released once the ADC has been internalized by the target cell, enhancing the efficacy and safety profile of the treatment.

Home
Products
Anti-Ab ADCs
IgG Fc
Protein G-Duocarmycin ADC

Protein G-Duocarmycin ADC (CAT#: ADC-AA-051)

This ADC product is comprised of a Protein G conjugated via a linker to Duocarmycin. The Duocarmycin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Duocarmycin binds to DNA, causes DNA damage. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Protein G

Name
Duocarmycins

Description
Duocarmycins belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-051. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Remarkable Precision and Safety

The Protein G-Duocarmycin ADC from Creative Biolabs targets cancer cells with high accuracy, delivering Duocarmycin effectively without systemic toxicity

Excellent

Effective Cancer Targeting

This ADC provides excellent receptor-mediated delivery of Duocarmycin, causing substantial DNA damage in cancer cells, pivotal for our research.

Excellent

Superb for Monoclonal Antibody Screening! Protein G-Duocarmycin ADC offers a cost-effective alternative to traditional methods with its precise cancer cell targeting and low toxicity

Excellent

Highly Recommended for Cancer Research! The conjugation of Protein G to Duocarmycin ensures precise delivery and potent action, essential for studying receptor-mediated endocytosis.

Excellent

Reliable and Economical

We've found the Protein G-Duocarmycin ADC indispensable for pre-screening monoclonal antibodies, providing consistent results without primary antibody toxicity.

Excellent

Innovative and Effective

The targeted action of Duocarmycin via Protein G and its subsequent DNA interaction make this ADC a powerful tool in advancing cancer treatment studies.

Q: 1: How does Duocarmycin induce cytotoxicity in targeted cells?
A: Once internalized, Duocarmycin, the cytotoxic component of the ADC, binds to DNA within the cancer cells. It causes alkylation and minor groove binding, which leads to DNA damage, disrupting the DNA replication process and ultimately causing cell death.
Q: 2: What are the advantages of using this ADC for pre-screening monoclonal antibodies?
A: The Protein G-Duocarmycin ADC offers a cost-effective and efficient method for pre-screening monoclonal antibodies as potential ADC candidates. It allows researchers to assess the therapeutic potential of antibodies by observing the cytotoxic effect of Duocarmycin on cells targeted by the antibodies under investigation.
Q: 3: Are there specific cancer types that are more responsive to treatment with Protein G-Duocarmycin ADC?
A: The efficacy of the Protein G-Duocarmycin ADC is particularly notable in cancers that express Fc receptors, which are targeted by the Protein G component of the ADC. Such cancers include certain leukemias, lymphomas, and some solid tumors.
Q: 4: What experimental conditions are recommended for using the Protein G-Duocarmycin ADC in laboratory research?
A: Optimal experimental conditions include using the ADC at concentrations determined through preliminary dose-response experiments. The cell culture should express Fc receptors to ensure ADC binding and internalization. Conditions such as incubation time and temperature should be optimized based on specific cell line characteristics.
Q: 5: How does the linker in the Protein G-Duocarmycin ADC enhance its stability and efficacy?
A: The linker used in this ADC is designed to be stable in the bloodstream, which prevents premature release of Duocarmycin. This stability ensures that the cytotoxic payload is only released once the ADC has been internalized by the target cell, enhancing the efficacy and safety profile of the treatment.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-021	anti-MIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-052	Protein A-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-056	Anti-MIgG (clone 187.1)-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-AA-055	Protein A-Duocarmycin ADC		Duocarmycins

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.